Where Seelos Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
In the last quarter, Seelos Therapeutics (NASDAQ:SEEL) received three somewhat bullish ratings from analysts, with no bearish or indifferent ratings. The company's average 12-month price target is $1.67, a decrease of 58.25% from the previous average of $4.00.
September 22, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Seelos Therapeutics received somewhat bullish ratings from analysts, but its average price target has decreased significantly.
While the company received somewhat bullish ratings from analysts, the significant decrease in the average price target could indicate a potential downside, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100